CytoCore Announces Annual Shareholders Meeting.CHICAGO -- CytoCore (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :CYCR), the biopharmaceutical research and medical device company for early detection and treatment of reproductive-tract cancers, will hold its annual shareholders meeting on Thursday, June 21 in San Francisco San Francisco (săn frănsĭs`kō), city (1990 pop. 723,959), coextensive with San Francisco co., W Calif., on the tip of a peninsula between the Pacific Ocean and San Francisco Bay, which are connected by the strait known as the Golden . The meeting starts at 10 a.m. PDT PDT abbr. Pacific Daylight Time PDT Pacific Daylight Time PDT n abbr (US) (= Pacific Daylight Time) → hora de verano del Pacífico PDT and will be held at the Hyatt Regency San Francisco at 5 Embarcadero Center The Embarcadero Center is a commercial complex of six towers (four office, two Hyatt hotels) and one office tower on a 9.8 acre (39,655 square meters) site that is located in the San Francisco's financial district close to the Embarcadero. . Dr. George Gorodeski, Chief Scientist and head of CytoCore's Medical Advisory board, will give a presentation on the state of CytoCore's technology. About CytoCore Inc. CytoCore develops cost-effective cancer screening systems which can be utilized in a laboratory or at the point-of-care, to assist in the early detection of cervical, endometrial endometrial /en·do·me·tri·al/ (en?do-me´tre-il) pertaining to the endometrium. endometrial, n relating to the end-ometrium or cavity of the uterus. , and other cancers. The InPath[TM] System is being developed to provide medical practitioners with highly accurate, low-cost, cervical and uterine cancer uterine cancer Malignant tumour of the uterus. Cancers affecting the lining of the uterus (endometrium) are the most common cancers of the female reproductive tract. screening systems that can be seamlessly integrated into existing medical models. More information is available at: www.CytoCoreInc.com Dr. Gorodeski, MD, PhD, Professor of Reproductive Biology, Oncology and Physiology and Bio-physics at Case Western Reserve University and a faculty member at University Hospital Case Medical Center of Cleveland is director of the Medical Advisory Board and Chief Scientist at CytoCore Inc. Dr. Gorodeski has a significant financial interest in this research consisting of equity and fees as consultant and Director of the Scientific Advisory Board of CytoCore. Dr. Gorodeski's invention licensed to CytoCore could generate royalty income for Dr. Gorodeski, for University Hospitals of Cleveland University Hospitals is a major not-for-profit medical center in Cleveland, Ohio, United States. With 150 locations throughout northeast Ohio, it encompasses a network of hospitals, outpatient centers and primary care physicians. , and for CASE University. Certain statements in this release are forward-looking. These statements are based on CytoCore's current expectations and involve many risks and uncertainties, such as the company's inability to obtain sufficient financing, the possibility that clinical trials will not substantiate CytoCore's expectations with respect to the InPath[TM] System, and other factors set forth in reports and documents filed by CytoCore with the Securities and Exchange Commission. Actual results may differ materially from CytoCore's current expectation depending upon a number of factors affecting the Company's business. These factors include, among others, risks and uncertainties detailed in the Company's periodic public filings with the Securities and Exchange Commission, including but not limited to the Company's Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended December 31, 2006. Except as expressly required by law, CytoCore undertakes no obligation to publicly update or revise any forward-looking statements contained herein. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion